Anebulo Pharmaceuticals I...

1.25
0.06 (5.04%)
At close: Apr 02, 2025, 3:59 PM
1.14
-8.80%
After-hours: Apr 02, 2025, 05:28 PM EDT

Anebulo Pharmaceuticals Income Statement

Financials in USD. Fiscal year is July - June.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending Jun 30, 2024 Jun 30, 2023 Jun 30, 2022 Jun 30, 2021 Jun 30, 2020
Revenue n/a n/a n/a n/a n/a
Cost of Revenue n/a n/a n/a n/a n/a
Gross Profit n/a n/a n/a n/a n/a
Operating Income -8.31M -11.78M -6.83M -3.61M -173.35K
Interest Income 97.79K 92.41K 7.33K 1.02K 7.72
Pretax Income -8.2M -11.73M -6.83M -30.25M -174.64K
Net Income -8.2M -11.73M -6.81M -30.26M -174.64K
Selling & General & Admin 4.76M 6.18M 3.87M 1.34M 23.35K
Research & Development 3.55M 5.6M 2.96M 2.27M 150K
Other Expenses n/a -41.15K -1.78K -1.34K n/a
Operating Expenses 8.31M 11.78M 6.83M 3.61M 173.35K
Interest Expense n/a n/a 7.33K 11.77K 1.29K
Selling & Marketing Expenses 4.8K n/a n/a n/a 23.21K
Cost & Expenses 8.31M 11.78M 6.83M 3.61M 173.35K
Income Tax n/a -104.19K -12.89K 10.75K -1.04K
Shares Outstanding (Basic) 25.82M 25.07M 23.34M 23.34M 23.72M
Shares Outstanding (Diluted) 25.82M 25.07M 23.34M 23.34M 23.72M
EPS (Basic) -0.32 -0.47 -0.29 -1.3 -0.01
EPS (Diluted) -0.32 -0.47 -0.29 -1.3 -0.01
EBITDA -8.05M -11.78M 5.55K -30.24M -173.35K
EBIT -8.05M -11.73M -6.83M -30.24M -173.35K
Depreciation & Amortization 258.28K 11.78M 6.83M 3.61M 1.04M